

Avrupa Birliđi Çerçeve Programları/Ufuk Avrupa



- Avrupa'nın **araştırma ve yenilik** politikaları ile uyumlu şekilde Ar-Ge faaliyetlerini desteklemek ve hızlandırmak için geliştirmiş olduđu **stratejik bir fonlama mekanizması**.

- Ar-Ge ve yenilik kapsamındaki faaliyetlerin desteklendiđi,
- **2021-2027** dönemini kapsayan,
- **95.5 Milyar Avro** bütçeli,
- Farklı tip organizasyonların fon alabildiđi **9. AB Çerçeve Programı**





Pillar II - Clusters

GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS:

boosting **key technologies** and solutions underpinning **EU policies & Sustainable Development Goals** (6 clusters and JRC – non-nuclear direct actions)



€53.5 billion




- Sanayi Kuruluşları, KOBİ'ler, Üniversiteler, Ar-Ge Merkezleri, STK'lar vb.
- Başvurular **İngilizce** ve doğrudan Avrupa Komisyonuna yapılıyor.
- Programın idari, yasal ve finansal tüm süreçleri **Avrupa Komisyonu** tarafından yürütülüyor
- **Konsorsiyumun** en az 3 farklı AB üye ya da asosiye üyeden (1 ülke mutlaka AB üyesi olmalı) oluşmalıdır.
- Konsorsiyumlarda **Proje Koordinatörü/Ortak** olarak yer alınabilir.

MSs, ACs, LMICs, and non-Associated Third Countries



- **Sürdürülebilir olmayan sağlık ve bakım harcamaları**
 - Yaşlanma
 - Kronik hastalıklar, kanser, diyabet, kardiyovasküler hastalıklar, ve nörolojik bozukluklar
 - Farklı tip tedaviler gerektiren durumlar
 - Yüksek maliyetli sağlık harcamaları
- **İklim değişikliği ve diğer çevresel faktörler kaynaklı sağlık sorunları**
- **Antimikrobiyal Direnç**
- **Sağlık hizmetlerine erişimdeki eşitsizlik**
- **Sağlık Endüstrisinin rekabetçiliğini devam ettirmek**



Cluster 1 'Health': addressing EU & global concerns

1. Unsustainable health and care costs  Increasing prevalence of chronic diseases and an ageing population	2. Role of environment on health  Lifestyle, pollutants, climate change	3. Increasing risks of infectious diseases  Resistance to antibiotics, (re)-emerging diseases	4. Health inequalities and access to health and care  Access to health promotion, prevention, treatment	5. Keeping a competitive European health and care industry  Keep Europe as the best innovator in healthcare area
---	--	--	--	---


Health and well-being priority areas

Alanın Genel Amacı

- Hastalıkların önlenmesi, tanısı ve tedavisi için yeni bilgiler üreterek ve yenilikçi çözümler geliştirerek, yaşam boyu sağlığın korunması, hastalık risklerinin azaltılması, sağlıklı toplumların, sağlıklı işgücünün desteklenmesi, sürdürülebilir, toplumun her kesiminin erişebileceği, daha düşük maliyetli sağlık hizmetleri ve sağlık sistemlerinin geliştirilmesi

- Ulusal İrtibat Noktası: Doç. Dr. N. Selcan TÜRKER

«ncphealth@tubitak.gov.tr»



KÜMELER

Sağlık



MİSYONLAR

Kanser Misyonu



ORTAKLIKLAR



HEDEFLER (Destinations)



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



1. Yaşam boyu sağlık
2. Sağlıklı çalışma ve yaşam ortamları
3. Bulaşıcı olmayan hastalıklar ve nadir hastalıklar
4. Bulaşıcı hastalıklarla mücadele
5. Sağlık için dijital çözüm ve teknolojiler
6. Yenilikçi Sağlık Bakım sistemleri



Health throughout
the Life Course



Environmental and Social
Health Determinants



Non-communicable
and Rare Diseases



Infectious diseases



Tools, Technologies
and Digital Solutions
for Health and Care




Health Care Systems

Küme 1: Çalışma Programı (2023-2024)



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



- Çalışma Programı (Work Programme):
- Hedefler (Destinations):
 - Beklenen Etkiler (Expected Impacts)
- Çağrılar (Calls):
 - Çağrı başlıkları (Topics)
 - Kapsam (Scope)
 - Beklenen Çıktılar (Expected Outcomes)
 - Çağrı Özel Şartları (Specific Conditions)
 - Fonlama Türü (RIA, IA, CSA...)
 - Bütçe

Küme 1: Çalışma Programı (2023-2024)

Horizon Europe - Work Programme 2023-2024 Health

Table of contents

Introduction	7
Destination 1 – Staying healthy in a rapidly changing society.....	13
Call - Staying Healthy (Single stage - 2023).....	16
Conditions for the Call.....	16
HORIZON-HLTH-2023-STAYHLTH-01-01: The Silver Deal - Person-centred health and care in European regions	17
Call - Staying Healthy (Two stage - 2024).....	20
Conditions for the Call.....	20
HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage: Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society	22
HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage: Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources.....	25
Destination 2. Living and working in a health-promoting environment.....	31
Call - Environment and health (Single stage - 2023).....	34
Conditions for the Call.....	34
HORIZON-HLTH-2023-ENVHLTH-02-01: Planetary health: understanding the links between environmental degradation and health impacts.....	35
HORIZON-HLTH-2023-ENVHLTH-02-02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)	39
HORIZON-HLTH-2023-ENVHLTH-02-03: Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties ..	44
HORIZON-HLTH-2023-ENVHLTH-02-04: Global coordination of exposome research.....	48
Call - Environment and health (Two stage - 2024)	51
Conditions for the Call.....	51
HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage: The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution	53
Destination 3. Tackling diseases and reducing disease burden	59
Call - Tackling diseases (Single stage - 2023).....	63
Conditions for the Call.....	63
HORIZON-HLTH-2023-DISEASE-03-01: Novel approaches for palliative and end-of-life care for non-cancer patients	64


Horizon Europe - Work Programme 2023-2024 Health

Destination 2. Living and working in a health-promoting environment

Calls for proposals under this destination are directed towards the Key Strategic Orientation KSO-D 'Creating a more resilient, inclusive and democratic European society' of Horizon Europe's Strategic Plan 2021-2024. Research and innovation supported under this destination should contribute to the impact area 'A resilient EU prepared for emerging threats' and in particular to the following expected impact, set out in the Strategic Plan for the health cluster: 'living and working environments are health-promoting and sustainable thanks to better understanding of environmental, occupational, social and economic determinants of health'. In addition, research and innovation supported under this destination could also contribute to the following impact areas: 'Good health and high-quality accessible health care', 'Climate change mitigation and adaptation', and 'Clean and healthy air, water and soil'. The environment we live and work in is a major determinant of our health and well-being. Environmental factors are estimated to account for almost 20% of all deaths in Europe. The impacting factors on both physical and mental health and wellbeing are not all identified nor their effects comprehensively understood and accounted for to support evidence-based policy- and decision-making. Therefore, Destination 2 aims at filling knowledge gaps in the understanding of the impacts on our health and well-being of those environmental, occupational and socio-economic risk factors that have the most significant or widespread societal impacts. In this work programme, Destination 2 focuses on pollution, disrupting chemicals, environmental degradation, climate and other environmental exposures in living and working environments. The results will support the EU's environment and health policies and overarching policy frameworks such as the European Green Deal, the Chemical Strategy for Sustainability, the EU Adaptation Strategy, the EU Biodiversity Strategy 2030, the 8th Environment Action Programme, the EU Strategic Framework on Health and Safety at Work as well as the WHO European Environment and Health Process (EHP). Strong collaborations across sectors and with other Horizon Europe clusters dealing with issues such as agriculture, food, environment, climate, biodiversity, mobility, security, urban planning, social inclusion and gender will be needed to ensure that maximal societal benefits are reached. Thus, in view of increasing the impact of EU investments under Horizon Europe, the European Commission welcomes and supports cooperation between EU-funded projects to enable cross-fertilisation and other synergies. This could range from networking to joint activities such as the participation in joint workshops, the exchange of knowledge, development and adoption of best practices, or joint communication activities. All topics are open to international collaboration to address global environment and health challenges.

Expected impacts:

Proposals for topics under this destination should set out a credible pathway to contributing to living and working in a health-promoting environment, and more specifically to one or several of the following impacts:



- Horizon Europe is implemented through **work programmes** which set out funding opportunities mainly through **calls for proposals**.
- A call for proposal will normally contain one or more **topics** with a common deadline. The budget of the call is distributed among topics. Where topics share a budget envelope, proposals for these topics will be competing against each other and will result in a single ranking list.
- Applicants **apply to a specific call and topic**.
- Each topic to which applicants can apply will include:
 - The topic **scope**
 - The topic **expected outcome**
 - The **expected impact** of the destination to which the topic belongs
 - The **type of action**
 - The topic **budget** (or budget shared by group of topics)

Horizon Europe - Work Programme 2023-2024
Health

Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR million) ⁸³	Indicative number of projects expected to be funded
		2024		
Opening: 30 Mar 2023				
Deadline(s): 19 Sep 2023 (First Stage), 11 Apr 2024 (Second Stage)				
HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage	RIA	60.00	7.00 to 8.00	8
Overall indicative budget		60.00		

General conditions relating to this call	
Admissibility conditions	The conditions are described in General Annex A.
Eligibility conditions	The conditions are described in General Annex B.
Financial and operational capacity and exclusion	The criteria are described in General Annex C.
Award criteria	The criteria are described in General Annex D.
Documents	The documents are described in General Annex E.
Procedure	The procedure is described in General Annex F.
Legal and financial set-up of the Grant Agreements	The rules are described in General Annex G.

Proposals are invited against the following topic(s):

All deadlines are at 17.00.00 Brussels local time.
The budget amounts are subject to the availability of the appropriations provided for in the general budget of the Union for years 2023 and 2024.

⁸³ Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Horizon Europe - Work Programme 2023-2024
Health

HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage: The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution

Specific conditions

Expected EU contribution per project	The Commission estimates that an EU contribution of between EUR 7.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
Indicative budget	The total indicative budget for the topic is EUR 60.00 million.
Type of Action	Research and Innovation Actions
Admissibility conditions	The conditions are described in General Annex A. The following exceptions apply: Applicants submitting a proposal under the blind evaluation pilot (see General Annex F) must not disclose their organisation names, acronyms, logos, nor names of personnel in Part B of their first stage application (see General Annex E).
Eligibility conditions	The conditions are described in General Annex B. The following exceptions apply: In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding. The Joint Research Centre (JRC) may participate as member of the consortium selected for funding. If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Award criteria	The criteria are described in General Annex D. The following exceptions apply: For the second stage, the thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
Procedure	The procedure is described in General Annex F. The following exceptions apply: This topic is part of the blind evaluation pilot under which first stage proposals will be evaluated blindly.

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 2 'Living and working in a health-promoting environment'. To that end, proposals under this topic should aim for delivering results that are tailored towards and contributing to all of the following expected outcomes:

- National and EU authorities apply user-friendly tools to produce and use generated data on the impact of pollutants on health;

⁸⁴ This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under 'Simplified costs decisions' or through this link: <https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ia-decision-be-en.pdf>

Scope: The European Green Deal set out by the European Commission recognises that man-made environmental pollution is an increasing threat for human health and wellbeing. Opinion polls⁸⁵ show that climate change, air pollution, and waste are the three most important environmental issues that European citizens are concerned about. Over three-quarters (78%) of respondents believe that environmental issues have a direct effect on their daily life and health.

Pollution affects a large number of people in Europe and beyond: A 2018 assessment attributed 16% of total global mortality to pollution-related disease. Over 7 million people die of exposure to polluted air every year worldwide⁸⁶. For 2019, the European Environment Agency has estimated that around 350 000 premature deaths in the EU can be attributed to air pollution (namely from particulate matter, nitrogen dioxide and ozone)⁸⁷. Today, more than 1 in 4 Europeans is exposed to traffic noise levels dangerous to their health in their homes, schools and workplaces⁸⁸. The increase of artificial light at night (ALAN) in cities has altered the natural light levels in the environment and extended human activities to the usually dark hours. It has been estimated that more than 80% of the world population is living under light

⁸⁵ E.g. Eurobarometer 501 – 2020- https://ec.europa.eu/commission/presscorner/detail/en/ip_20_331

⁸⁶ Air pollution (who.int)

⁸⁷ For more details, see Briefing no. 19/2021: Health impacts of air pollution in Europe, 2021

⁸⁸ EEA 2020 report on Healthy environment, healthy lives: how the environment influences health and well-being in Europe

- Hızlı deęişen bir toplumda, **hastalıkların önlenmesi** ve her yaştan vatandaşın daha iyi **saęlık hizmetine erişebilmesi** için,
 - saęlıklı yaşam davranışları ve alışkanlıkları,
 - saęlıklı beslenme,
 - saęlıklı bir çevre,
 - kanıt temelli saęlık politikaları,
 - daha etkili saęlık çözümlerinin geliştirilmesi
- ✓ Vatandaşların yaşlılık ya da yaşamın dięer savunmasız evreleri dahil olmak üzere **daha az hastalık yükü** ile daha uzun süre saęlıklı ve aktif bir yaşam sürdürmesi
- ✓ Yaşa baęlı hastalıkların ilerlemesini önlemek ve geciktirmek için yeni araçların, **dijital çözümlerin ve kanıta dayalı saęlık ve bakım hizmetlerinin** benimsenmesi
- ✓ **Saęlık okur-yazarlığının** artırılarak, vatandaşların bilgi temelli süreçlere olan güveninin arttırılması
- ✓ Vatandaşların, kendi **fiziksel ve zihinsel saęlıklarını** daha iyi yönetmek, saęlık durumlarını takip etmek ve hekimler ile etkileşimde bulunabilmeleri için desteklenmesi




Destinasyon 2: Sağlığı teşvik eden ve geliştiren bir ortamda yaşamak ve çalışmak

- Sağlık, içerisinde çalıştığımız, yaşadığımız ve etkileşimlerde bulunduğumuz çevresel koşulların bir neticesidir.
- **Çevresel faktörlerin** Avrupa'daki tüm ölümlerin yaklaşık %20'sinden sorumlu olduğu tahmin edilmektedir.
 - **Çevresel, mesleki ve sosyo-ekonomik risk faktörlerinin** sağlık üzerindeki etkilerinin anlaşılması, hastalık belirteçlerinin anlaşılması ve azaltılması
 - **Tehlikeli kimyasallar ile hava, su ve toprak kirliliği** ve kontaminasyonundan kaynaklanan sağlık tehditleri ve yükünün azaltılması
 - **Yaşam ve çalışma ortamlarının** daha sağlıklı, daha kapsayıcı, daha güvenli ve sürdürülebilir hale getirilmesi
 - Vatandaşların sağlığının korunması, erken ölümler ve **çevre kirliliğine bağlı hastalıkların önlenmesi**

İlgili AB politikaları:

- AB Yeşil Mutabakatı
- Sürdürülebilirlik için Kimyasallar Stratejisi
- Sıfır Kirlilik Aksiyon Planı
- İklim Uyum Stratejisi



- **Bulaşıcı ve bulaşıcı olmayan hastalıklar**, AB'de ve dünya çapında en fazla erken ölüm ve sakatlığa yol açan faktörler arasında yer almaktadır.
 - Ar-Ge ve inovasyon yoluyla yeni önleyici tedbirlerin, **halk sağlığı** müdahalelerinin, tanı yöntemlerinin, **aşı, tedavi, ilaçların** geliştirilmesi
 - Yenilikçi tanı ve tedavilerin, **kişiselleştirilmiş tıp yaklaşımlarının**, sağlık hizmetleri için **dijital çözümlerin** geliştirilmesi de dahil olmak üzere etkili hastalık yönetimi
 - Bulaşıcı olmayan hastalıklardan kaynaklanan erken ölümlerin üçte bir oranında azaltılması, **mental sağlığın** ve toplumsal refahın korunması
 - **Salgın hastalıklar ve antimikrobiyal direnç** karşı işbirliği
 - **Vatandaşların** sağlıklarıyla ilgili karar almalarının desteklenmesi, bilgiye dayalı hastalık yönetimi stratejilerine ve politikalarına uyum sağlayabilmeleri



- **Sağlık sistemleri**nin daha etkili, verimli, erişilebilir ve sürdürülebilir hale gelmesi gerekmektedir.
 - **Güvenli, uygun maliyetli ve insan merkezli** çözümlerin geliştirilmesi ve benimsenmesi sayesinde yenilikçi, sürdürülebilir ve yüksek kaliteli sağlık hizmetlerine eşit erişim
 - Hastane merkezli sağlık hizmetlerinden, bireyi merkeze alan entegre sağlık hizmetlerine geçiş
 - Sağlık sistemlerinin modernize edilerek, **dijital olarak dönüştürülmesi** ve yenilikçi araçlar, teknolojiler ve dijital çözümlerle donatılması
 - **Sağlığın öz yönetiminin** desteklenmesi ve savunmasız grupların özel ihtiyaçlarının ele alınması
 - Sağlık politikasında bütüncül bir yaklaşım benimsemesi



- Teknoloji, yenilik için kilit bir güçtür ve sağlık hizmetlerinde bireylerin ihtiyaçlarına göre uyarlanmış, **toplumsal etkisi yüksek, daha etkili ve daha uygun maliyetli teknolojiler ve dijital çözümler** sağlayabilir.
 - Vatandaşların, daha güvenli, sürdürülebilir, verimli, uygun maliyetli teknolojilerden, dijital çözümlerden ve araştırmalardan yararlanabilmesi
 - AB'nin **sağlık teknolojileri** geliştirmede lider konuma ulaşması
 - Hastalık yükünün, **insan merkezli çözümlerin** geliştirilmesi yoluyla azaltılması
 - Sağlık araştırmaları ve inovasyonlarının verimliliği ile **sağlık hizmetlerinin kalitesi** ve sonuçlarının iyileştirilmesi



Destinasyon 6: Yenilikçi, sürdürülebilir ve küresel olarak rekabetçi bir sağlık endüstrisi sağlamak

- **Sağlık endüstrisi**, hastaların ve sağlık hizmeti sağlayıcılarının yararına sağlık teknolojileri sağlama kapasitesine ve gücüne sahiptir.
 - Yenilikçi sağlık teknolojileri ve hizmetlerinin (tıbbi teknolojiler, ilaç, biyoteknolojik ürünler, dijital sağlık teknolojileri vb.) geliştirilmesi ve benimsenmesi
 - Sağlık sektörünün (KOBİ'ler dahil), tıbbi malzemeler ve dijital teknolojilerde daha **rekabetçi ve sürdürülebilir** hale gelmesi
 - Sağlık sektörünün, değer zinciri boyunca **verimliliğinin arttırılması**
 - Sağlık hizmetlerinin **güvenliğinin ve kalitesinin** iyileştirilmesi
 - Yeni metotların, kılavuzların ve **ortak standartlarının** oluşturulması (özellikle yüksek risk taşıyan tıbbi cihazlar için)
 - **Yeşil ve dijital dönüşüm** ile uyumlu şekilde üretim süreçlerinin hızlandırılması
 - Yetkili kuruluşların yeni sağlık teknoloji ve girişimlerine **erişiminin kolaylaştırılması**





Destination 3

Expected impacts include:

- Reduced health burden of diseases in the EU and worldwide
- Reduced premature mortality from NCDs
- Promoted mental health and well-being
- Strengthened research and innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases
- Reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide
- Better knowledge of disease threats that allows to be involved and empowered to make and shape decisions for health, and better adhere to knowledge-based disease management strategies and policies

• HORIZON-HLTH-2024-DISEASE-13-01:

Implementation research for management of multiple long-term conditions in the context of **non-communicable diseases** (Global Alliance for Chronic Diseases - GACD)

Destination 3:

- HORIZON-HLTH-2024-DISEASE-13-01: single stage
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)
- Closure: 26 November 2024
- Instrument: RIA
- Total: 20M€
- Project size: 3-4 M€

25 Nisan 2024-26 Kasım 2024



Destination 4: Ensuring access to innovative, sustainable and high-quality health care

- **Key Strategic Orientation:** 'Creating a more resilient, inclusive and democratic European society'
- **Impact areas:**
 - Good health and **high-quality accessible health care**
 - A resilient EU prepared for emerging threats
 - Health care systems provide equal access to innovative, sustainable and high-quality health care **thanks to the development and uptake of safe, cost-effective and people-centred solutions, with a focus on population health, health systems resilience, as well as improved evidence-based health policies.**
 - **Climate change mitigation and adaptation**
 - High quality digital services for all
 - A competitive and secure data economy

Destination 4:

HORIZON-HLTH-2024-CARE-14-01: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems


Closure: 26 November 2024

- Instrument: PCP
- Total: 15M€
- Project size: 3-5 M€

25 Nisan 2024-26 Kasım 2024

• HORIZON-HLTH-2024-CARE-14-01:

Pre-commercial procurement for environmentally sustainable, climate neutral and **circular health and care systems** (Pre Commercial Procurement-PCP)




Ufuk Avrupa

«Kanser Misyonu»



- **Kanser**; yaş, cinsiyet ve sosyal statüden bağımsız olarak birçok kişiyi etkilemekte; hastalar, aileleri ve sağlık sistemleri üzerinde ciddi ve giderek artan bir yük oluşturmaktadır. Önlem alınmazsa Avrupa'da her yıl kanser teşhisi konan kişilerin sayısının 3,5 milyondan 2035 yılına kadar 4,3 milyonun üzerine çıkacağı tahmin edilmektedir.



Concrete solutions for our greatest challenges

CHALLENGES

- 2.7 million people in the EU are diagnosed each year (this number will increase);
- 1.3 million people die from cancer each year (this number will increase);
- Total cost of cancer in Europe in 2018, estimated at €199 billion.

OPPORTUNITIES

- Improve cancer control;
- Put citizens and patients at the centre of research and innovation;
- Give research and innovation a central role in new policies by supporting Europe's Beating Cancer Plan.

26%

Cancer is the **second leading cause of death**, accounting for 26% of all deaths.

2x

Participation in cervical cancer screening varies almost two-fold by education level.

75%

Cancer mortality is almost 75% higher among men in the EU

199 billion

In 2018, EU countries spent in total 199 billion euros on cancer care.


50%

Smoking is 50% higher among people from lower income groups.

2020

Cancer screening dropped in most EU countries in 2020 compared to 2019 due to Covid-19.

Five Missions Areas



- Ufuk Avrupa Programı kapsamında, **küresel sorunlara** daha ölçülebilir hedefler ile Ar-Ge ve yenilik temelli somut çözümler bulunabilmesi ve AB Çerçeve Programlarının topluma daha iyi anlatılabilmesi amacıyla belirlenen beş misyon arasında yer alan Kanser misyonu ile **2030 yılına kadar üç milyondan fazla kişinin hayatının iyileştirilmesi** amaçlanmaktadır.



https://cancer-code-europe.iarc.fr/images/doc/2_methodology.pdf



EUROPEAN UNION

Cancer Mission - WP2021-2024

- Mission-guiding principles
- Mission clusters
- Synergy Europe's Beating Cancer Plan

Develop new methods and technologies for screening and early detection
HORIZON-MISS-2021-CANCER-02-01

Improving and upscaling primary prevention of cancer through implementation research
HORIZON-MISS-2022-CANCER-01-01

Enhance cancer prevention through behaviour change
HORIZON-MISS-2023-CANCER-01-02


Early detection heritable cancers in European regions
HORIZON-MISS-2024-CANCER-01-03

Pragmatic clinical trials to optimise treatment for cancer patients
HORIZON-MISS-2022-CANCER-01-03

Strengthen research capacities of comprehensive cancer infrastructures
HORIZON-MISS-2022-CANCER-01-02

Pragmatic clinical trials minimally invasive diagnostics
HORIZON-MISS-2023-CANCER-01-03

Support a pragmatic clinical trial programme by cancer charities
HORIZON-MISS-2024-CANCER-01-04



EU MISSIONS
CANCER

Develop and validate a set of quality-of-life measures for cancer patients and survivors
HORIZON-MISS-2021-CANCER-02-02

Towards the creation of a European Cancer Patient Digital Centre
HORIZON-MISS-2022-CANCER-01-04:

Improve quality of life for survivors of childhood cancer (Best practices and tools)
HORIZON-MISS-2023-CANCER-01-04

Improving the understanding and management of late-effects in adolescents and young adults
HORIZON-MISS-2024-CANCER-01-05

An information portal for the European Cancer Patient Digital Centre
HORIZON-MISS-2024-CANCER-01-06

Preparing UNCAN.eu, a European initiative to understand cancer
HORIZON-MISS-2021-UNCAN-01-01

Better understand healthy versus cancer cells at individual and population level
HORIZON-MISS-2021-CANCER-02-03

Better understand tumour-host interactions in cancer patients
HORIZON-MISS-2023-CANCER-01-01

Use cases for the UNCAN.eu research data platform
HORIZON-MISS-2024-CANCER-01-01

Creation of national cancer mission hubs - HORIZON-MISS-2022-CANCER-01-05

National cancer data nodes - HORIZON-MISS-2024-CANCER-01-02

- **HORIZON-MISS-2024-CANCER-01-01:** Use cases for the UNCAN.eu research **data Platform**
- **HORIZON-MISS-2024-CANCER-01-02:** Support dialogue towards the development of national **cancer data nodes**
- **HORIZON-MISS-2024-CANCER-01-03:** Accessible and affordable tests to advance **early detection** of heritable cancers in European regions
- **HORIZON-MISS-2024-CANCER-01-04:** Support a **pragmatic clinical trial** programme by cancer charities
- **HORIZON-MISS-2024-CANCER-01-05:** Improving the understanding and management of **late-effects** in adolescents and young adults (AYA) with cancer
- **HORIZON-MISS-2024-CANCER-01-06:** An information portal for the European Cancer **Patient Digital Centre**

HORIZON-MISS-2024-CANCER-01-01	RIA	30.00 ¹⁵²	Around 30.00	1
HORIZON-MISS-2024-CANCER-01-02	CSA	3.00 ¹⁵³	Around 3.00	1
HORIZON-MISS-2024-CANCER-01-03	IA	35.00 ¹⁵⁴	10.00 to 12.00	3
HORIZON-MISS-2024-CANCER-01-04	CSA	3.00 ¹⁵⁵	Around 3.00	1
HORIZON-MISS-2024-CANCER-01-05	RIA	36.00 ¹⁵⁶	4.00 to 6.00	6
HORIZON-MISS-2024-CANCER-01-06	IA	12.00 ¹⁵⁷	Around 12.00	1
Overall indicative budget		119.00		

18 Nisan 2024-18 Eylül 2024

REWATCH

EU Missions and cross-cutting activities info days

The event aims to inform potential applicants about the new topics included in the EU Missions and Cross-cutting Activities work programme 2024

 25 April 2024 - 26 April 2024

 10:30 (GMT+03:00)

<https://research-innovation-community.ec.europa.eu/events/3WjiVunxm0t5j4zQIVax3Q/overview>

 EUROPEAN UNION

EU MISSIONS

Concrete solutions for our greatest challenges



21 May 2024 - 22 May 2024

Horizon Europe Missions Brokerage Event 2024

#EUMissions #HorizonEU

<https://missions-horizon-europe-brokerage-2024.b2match.io/page-4181>

KÜMELER

Sağlık



MİSYONLAR

Kanser Misyonu



ORTAKLIKLAR



Ufuk Avrupa

«ORTAKLIKLAR»



- AB ve sağlık endüstrileri arasında sağlık alanındaki araştırma ve yenilik projelerine fon sağlayan bir kamu-özel sektör kurumsallaşmış ortaklığı.
 - İlaç firmaları-Avrupa İlaç Endüstrileri ve Dernekleri Federasyonu (EFPIA)
 - Aşı sektörü – Vaccines Europe
 - Medikal görüntüleme, radyoterapi, sağlıkta BİT ve elektro-medikal şirketler -COCIR
 - Medikal teknoloji şirketleri-MedTechEurope
 - Biyoteknoloji şirketleri-EuropaBio



<https://www.ih.europa.eu/>

<https://ufukavrupa.org.tr/tr/ortakliklar/yenilikci-saglik-girisimi-innovative-health-initiative-joint-undertaking-ih-ju>

- **Konsorsium ile başvuru:**

- *en az 3 farklı AB üye/asosiye üye*
- *1 ülke mutlaka AB üyesi olmalı*

Consortium composition (collaborative projects)

- at least **one independent legal entity** established in a **Member State**, and
- at least **two other independent legal entities** each established either in a **different Member State** or an **Associated Country**.

EU COUNTRIES

- Member States (MS) including their outermost regions
- The Overseas Countries and Territories (OCTs) linked to the MS.

NON-EU COUNTRIES

- Countries associated to Horizon Europe (AC)
- Low and middle income countries: See [HE Programme Guide](#).

COUNTRIES ASSOCIATED TO HORIZON EUROPE

- Association agreements produce legal effects
- Transitional arrangements
- UK is treated as an associated country throughout the process - Grant agreements can only be signed if the association has come into force.
- Switzerland is currently not covered by the transitional arrangement.



Attracting stakeholders


Any legal entity, regardless its place of establishment, carrying out work relevant to the Call objectives may be part of applicant consortia

But... not all participating entities are eligible for funding

*applicant consortia must ensure that at least **45%** of the action's eligible costs and costs for additional activities related to the action are provided by contributions (IKOP, FC, IKAA) from **private members** which are members of IHI JU, their constituent or affiliated entities, and contributing partners*



- **Kamu-Özel sektör ortaklığı**
- IHI-JU Çağrılarının tamamı **RIA** türündedir.
- Tek aşamalı/İki aşamalı çağrılar
- Tüm çağrılara ve çağrı bilgilerine IHI Resmi WEB sayfasından ve Funding and Tenders sayfası üzerinden erişilebilmektedir.
- **Sağlık Endüstrisinden aktörlerle işbirliği**




The screenshot shows the 'Call documents' page of the Innovative Health Initiative (IHI). The page header includes the IHI logo and navigation links: 'Apply for funding', 'Shape our future research', 'Projects and results', 'Resources for projects', 'News & events', and 'About IHI'. Below the header, the main title 'Call documents' is displayed, followed by a subtitle: 'Guidance, templates and links for people planning on applying to be part of an IHI project.' A large, stylized graphic of a person is visible on the right side. The 'Key documents and links' section provides a list of resources: 'IHI guide for applicants' (last update 26 July 2023), 'IHI guide for contributing partners' (last update 20 July 2023), 'Frequently asked questions' (last update 20 July 2023), 'IHI guidelines for in-kind contributions to additional activities (IKAA)' (last update 20 April 2023), and a checklist for assessing IHI JU eligibility. A 'Questions?' section on the right encourages users to consult the documents and provides a 'Contact us' button. The 'Call texts' section at the bottom lists links for IHI - call 1 through IHI - call 5.

<https://www.ih.europa.eu/apply-funding/open-calls>

- A city-based approach to reducing **cardiovascular** mortality in Europe
- Novel endpoints for **osteoarthritis (OA)** by applying **big data** analytics
- Modelling **regulatory sandbox** mechanisms and enabling their deployment to support breakthrough innovation
- Patient-centred **clinical-study** endpoints derived using **digital health technologies**

Overview:

Active IHI projects and mature proposals mapped to therapeutic areas/themes (Calls 1-8)



+ Osteoarthritis

Ortak Arama ve Proje Sonuçları

Finding project partners

You'll need to build or join a consortium!

- Network with your contacts & IHI Call Days participants:
 - <https://ihi-call-days.ihi.b2match.io/>
 - Use EU Funding & Tenders portal **partner search tool**:
 - <https://europa.eu/!QU87Nx>
- Get in touch with your IHI national contact point:
 - <https://europa.eu/!D7jyMy>
- Network on social media:
 - www.twitter.com/IHIEurope
 - be.linkedin.com/company/innovative-health-initiative

Projects and results

The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section showcases the IMI project portfolio and IMI's impacts in key areas. Once IHI projects are up and running, we will also promote them here.

Project factsheets

Meet our projects and learn about their goals and results as well as their funding details and participants.

More >

Maps and statistics

Our projects have partners across Europe and beyond. Find them with the help of this interactive tool.

More >

Health spotlights

Our project results have made a difference in diverse areas, including diabetes, dementia and health data to name a few.

More >

Immune-Image

Specific imaging of immune cell dynamics using novel tracer strategies

Summary

Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The Immune-Image project aims to pioneer the use of non-invasive imaging technologies to track the activity of immune cells in the body. Ultimately, the project will make it easier to predict how patients will respond to treatment and monitor their progress during treatment.

To do this, the project will develop tracers capable of highlighting specific immune cells in a range of imaging types, including magnetic resonance imaging (MRI), positron emission tomography (PET), optical imaging (OI) and computed tomography (CT). They will also analyse biopsies and blood samples to build up complete immunological profiles of patients and to correlate imaging findings with pathology; this information will contribute to the development of personalised immunotherapies.

Participants

EFPIA companies

- Bayer Aktiengesellschaft, Leverkusen, Germany
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Immaginix, Inc., Ingleswood Ca, United States
- Janssen Pharmaceutica NV, Beerse, Belgium
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich Kent, United Kingdom
- Takeda Pharmaceuticals International AG, Gattipark-Opfikon (Zurich), Switzerland

Universities, research organisations, public bodies, non-profit groups

- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Paris, France
- Eberhard Karls Universität Tübingen, Tübingen, Germany
- Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca, Barcelona, Spain
- Fundació Privada Institut D'Investigació Oncològica De Vall-Hebron (Vhio), Barcelona, Spain
- Stichting Vumc, Amsterdam, Netherlands
- University Of Cambridge, Cambridge, United Kingdom
- Vlb Vzw, Zwijnaarde - Gent, Belgium
- Vrije Universiteit Brussel, Brussels, Belgium
- Westfälische Wilhelms-Universität Münster, Münster, Germany

Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)

- Anvaros Medical AB, Mölndal, Sweden
- Lawrencum Legal BV, Amsterdam, Netherlands
- Stichting Lygature, Utrecht, Netherlands
- Tloppart BV, Bilthoven, Netherlands

Patient organisations

- European Cancer Patient Coalition, Brussels, Belgium

Third parties

- Cloudseffing BV, Rijswijk, Netherlands
- Université Paris-Saclay, Saint Aubin, France

Facts & figures

Start Date	01/10/2019
End Date	30/09/2024
Call	IMI2 - Call 14
Grant agreement number	831514
CORDIS project page	Link
Type of Action:	RIA (Research and Innovation Action)
Contributions	€
Funding	15 000 000
EFPIA in kind	12 154 527
Other	48 274
Total Cost	27 200 801

Project links

Project website
www.immune-image.eu

Twitter
[@ImmuneImage](https://twitter.com/ImmuneImage)


Project video

[Immune Image](#)



IHI Call Days - Call 8
17-21 June 2024
online

<https://ufukavrupa.org.tr/tr/haberler/yenilikci-saglik-girisimi-ihl-8-cagrilari-bilgi-gunu-ve-konsorsiyum-kurma-etkinligi>



The screenshot shows the IHI Call Days Matchmaking Platform interface. At the top, there is a navigation bar with links: Home, Matchmaking Platform (highlighted), Marketplace, Call 7 - Pitching, General FAQ, and Contact. Below the navigation bar, the title 'Matchmaking Platform' is displayed. The main content area contains the following text: 'Our matchmaking platform allows you to book meetings at any time with any of the participants.' and 'In fact, it will be permanently **available** for this and future calls and you can register at any time, even after the info sessions have finished.' Below this, there is a link: 'You can access a detailed guide on how to use the matchmaking platform here'. At the bottom, there are two sections: '1) Registration' with the instruction 'Register via the [Register](#) button.' and '2) Create your participant profile' with the instruction 'Create a clear and concise participant profile to raise your visibility on the b2match platform.'

<https://ihi-call-days.ihi.b2match.io>

- European Partnership for Personalised Medicine-EP PerMed, **Kişiselleştirilmiş tıp** alanındaki araştırmalara ve yenilikçi yaklaşımlara destek verilmesi amaçlanmaktadır.
- **Multidisipliner** ve **translasyonel** araştırmalara, demonstrasyon projelerine ve pilot uygulamalara destek verilecektir.
- TÜBİTAK bu projede, **uluslararası çok ortaklı** Ar-Ge, inovasyon ve işbirliği çağrılarına **1071** mekanizması aracılığıyla dahil olacaktır.



- **TRANSCAN-3 Projesi**, kanserin anlaşılması, önlenmesi, tanı ve tedavisine yönelik **translasyonel kanser araştırmalarının** desteklenmesini hedeflemektedir.
- TÜBİTAK bu projede, **uluslararası çok ortaklı** Ar-Ge, inovasyon ve işbirliği çağrılarına **1071** mekanizması aracılığıyla dahil olacaktır.
- Kanserde kombinasyon tedavisine yönelik hasta **preklinik modellerin** geliştirilmesi amaçlanmaktadır.



ÖNEMLİ HUSUSLAR

**Horizon
Europe**



Kabul edilebilirlik (Admissibility) gereksinimleri;

- Başvurular eksiksiz olmalı ve tüm bölümleri, zorunlu ekleri ve destekleyici belgeleri içermelidir.
- Başvurular, iletişim faaliyetleri de dahil olmak üzere **sonuçların kullanılması ve yaygınlaştırılması için bir plan** içermelidir. (iki aşamalı prosedürlerin ilk aşamasındaki başvurular için veya özel çağrı koşullarında aksi belirtilmedikçe geçerli değildir).
- Normalde eylem türüne göre **belirli sayfa sınırları** geçerlidir (konu koşullarında belirtilir ve BT aracı tarafından kontrol edilir).

Uygunluk (Eligibility) gereksinimleri;

- **Uygun faaliyetler**, çağrı koşullarında açıklananlardır.
- Çağrı koşullarında belirtilen **minimum ortak sayısı** (bir AB Üyesi Devlette kurulu en az bir bağımsız tüzel kişilik ve bir Üye Devlet veya Asosye Ülkede kurulu en az iki bağımsız tüzel kişilik).
- Son başvuru tarihi 2022 ve sonrasında olan çağrılar için Üye Devletler ve Asosye ülkelerden kamu kurumları, araştırma kuruluşları veya yüksek öğretim kurumlarından katılımcıların bir toplumsal **cinsiyet eşitliği planı** yürürlükte olmalıdır.



https://rea.ec.europa.eu/news/common-mistakes-avoid-when-applying-horizon-europe-funding-2023-02-09_en

Değerlendirme Kriterleri



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



1. MÜKEMMELİYET “Excellence”

- Projenin bilimsel kalitesi ve amacı
- Çağrının hedefleriyle uyumu
- Yenilikçi yönü
- Metodoloji
- Araştırmada cinsiyet eşitliği ve açık bilim
- TRL seviyesi
- Veri yönetimi

What
What is the project
about?

EXCELLENCE

- ✓ Clarity and pertinence of the **project's objectives**, and the extent to which the proposed work is ambitious, and goes beyond the state-of-the-art.
- ✓ Soundness of the proposed **methodology** including the underlying concepts, models, assumptions, interdisciplinary approaches, appropriate consideration of the **gender dimension** in research and innovation content, and the quality of **open science practices** including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

2. ETKİ “Impact”

- Çağrıda hedeflenen çıktılara katkı
- Beklenen çıktılar
- Çıktıların çağrıda belirtilen hedeflerle nasıl/ne kadar örtüştüğü
- Uzun dönemli etkiler
- IPR yönetimi

Why
Why should we do the
project? What evidence
do we collect and
measure in the project to
demonstrate the projects
value?

IMPACT

- ✓ Credibility of the **pathways** to achieve the expected **outcomes and impacts** specified in the work programme, and the likely scale and significance of the contributions due to the project.
- ✓ Suitability and quality of the **measures to maximize expected outcomes and impacts**, as set out in the dissemination and exploitation plan, including communication activities.

3. UYGULAMA “Implementation”

- İş planının etkinliği ve tutarlılığı
- Görevlerin ve kaynakların dağılımındaki uyum
- Risk yönetimi
- Konsorsiyumun yapısı
- Bütçenin dağılımı

How
How to achieve the
objectives?

QUALITY AND EFFICIENCY OF THE IMPLEMENTATION

- ✓ Quality and effectiveness of the **work plan**, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall.
- ✓ Capacity and role of each **participant**, and extent to which the **consortium** as a whole brings together the necessary expertise.

Uygun çağrılarını bulmak



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



ec.europa.eu/info/funding-tenders/opportunities/portal/screen/programmes/horizon

European Commission | Funding & tender opportunities
Single Electronic Data Interchange Area (SEDIA)

English EN
Register Login

SEARCH FUNDING & TENDERS HOW TO PARTICIPATE PROJECTS & RESULTS WORK AS AN EXPERT SUPPORT

Get started

Find call by programme structure

Horizon Europe consists of three pillars and one horizontal activity:

Pillar 1
Excellent Science

European Research Council
Marie Skłodowska-Curie Action
Research Infrastructures

Pillar 2
Global Challenges and European Industrial Competitiveness

Clusters:

- Health
- Culture, Creativity and Inclusive Society
- Civil Security for Society
- Digital, Industry and Space
- Climate, Energy and Mobility
- Food, Bioeconomy, Natural Resources, Agriculture and Environment

Pillar 3
Innovative Europe

European Innovation Council
European Innovation ecosystems
European Institute of Innovation and Technology

Widening Participation and Strengthening the European Research Area

Widening participation and spreading excellence

Reforming and Enhancing the European R&I system

Find a call by missions areas

Within the clusters of pillar II, Horizon Europe incorporates missions to increase the effectiveness of funding by pursuing clearly defined targets with a concrete impact on citizen's daily lives.

The aim is to achieve bold, inspirational and measurable goals within a set timeframe.

The following 5 mission areas have been identified, each with a dedicated mission board and assembly. The board and assembly help specify, design and implement the specific missions which will launch under Horizon Europe in 2021:

- Adaptation to climate change including societal transformation
- Cancer
- Climate-neutral and smart cities
- Healthy oceans, seas, coastal and inland waters
- Soil health and food

Simplified funding

Horizon Europe uses more and more simplified forms of funding.

Here you can find all you need to know about lump sum funding in one page.

[Lump Sum Funding](#) [Unit Personnel Costs](#)

Information on unit personnel costs will be added when the option becomes available.

Formal consortium building mechanisms



Consortia Size - Actual

Statistics on actual consortia size (excluding IHI):



Coordinator	Partners/Beneficiaries
Contacts the EC on behalf of the consortium.	Provide their input for the communication with the EC.
Directly signs the Grant Agreement.	Sign the GA by signing the Accession Form.
Signs Amendments to the GA, if any, on behalf of the other beneficiaries.	Provide coordinator with input to prepare Amendments.
Coordinates and manages the project implementation.	Together contribute to a smooth and successful implementation of the project.
Submits the deliverables and reports in the system.	Provide input for deliverables, prepare their deliverables for the coordinator's revision.
Distributes payments to the other beneficiaries.	Spend their budget according to the Horizon Europe rules.
Reviews the individual financial statements from each partner.	Prepare their own financial statements.
Verifies that all the requested documents/information have been provided by partners (e.g. the use of resources, etc.)	Prepare requested documentation for the coordinator's revision.

Portal üzerinden Ortak Aramak



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



Funding & tender opportunities
Single Electronic Data Interchange Area (SEDIA)

English

Register

Login



SEARCH FUNDING & TENDERS

HOW TO PARTICIPATE

PROJECTS & RESULTS

WORK AS AN EXPERT

SUPPORT

Get started



Grant Management Services will be e

Key steps
Reference documents
Participant register
Partner search

2023, between 07:30 and 08:10.



Due to technical maintenance, Funding and Tenders Portal services may not be available 15/08/2023 20:00 until 15/08/2023 23:55 CET. We apologize for the inconvenience caused.

Partner search



cancer



Search



Organisations



Persons

Advanced search ^

Programme / Topic

Programme

Select a Programme...



Topic

Select a Topic...



Location

Country

Select a Country...



City

Type a City...

Organisation

Organisation type

Select an Organisation type...



Person profile

Professional profile

Select a Professional profile...




Profiles with published Partner search announcements (220)

Ortak Arama_Geçmiş Projeler



CORDIS is the primary source of results from EU-funded projects since 1990



<https://cordis.europa.eu/projects/en>

Home > Projects > Success stories > Success stories: Türkiye, Health & life sciences, Array

Success stories: Türkiye, Health & life sciences, Array

Flexible research leads to pocket PCR test for COVID-19



While researchers were busy developing a handheld device to rapidly detect biomarkers to guide the therapy in lung cancer, the pandemic struck. Realising their device could be adapted to test for coronavirus, researchers refocused their work. The result is the market's smallest portable PCR device.

+ Add to pdf basket

A safe source of drinking water for rural Malawi



The EU-funded WATERSPOUTT project's partners in Malawi are designing and testing an innovative solar-ceramic water filtration system capable of providing local communities with a reliable source of clean water at the household level.

+ Add to pdf basket

A fast, accurate and life-saving approach to diagnosing sepsis



EU-funded researchers have developed three innovative devices that will help doctors to diagnose sepsis more quickly and with greater precision, save lives and improve patients' chances of recovery from the deadly disease.

PDF Basket

No article selected

Filter stories

Country

Türkiye



Theme

Health & life sciences



Framework programme

- Any -



Project acronym

- Any -



Project number

Project coordinator

Niyet Beyanı (Expression of Interest)



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



Partner Search Form
Horizon Europe
Health

Date: Deadline:

CONTACT

Organisation: Department:
Contact person: Email:
City: Website:
Country:

Organisation type

Research organisation type	☐ Research Organisation ☐ University ☐ Company ☐ Other	Is your company a Small and Medium Sized Enterprise (SME)? ☐ YES ☐ NO Number of employees:
----------------------------	---	---

Your enterprise is an SME if:
- is engaged in economic activity
- has less than 250 employees
- has either an annual turnover not exceeding €50M, or a balance sheet total not exceeding €43M
- is autonomous
For the definition of SMEs, look at: http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

Short introduction of key areas of institute's research:

Former participation in an FP European project?
☐ YES ☐ NO

Project title / Acronym:
Activities performed:

Expertise / Commitment offered

Description of your expertise:
Keywords specifying your expertise:

Commitment offered: ☐ Research ☐ Demonstration ☐ Training

Partner Search Form
Horizon Europe
Health

☐ Technology ☐ Dissemination ☐ Other:

Interested in participation in project types:
☐ Research & Innovation Action ☐ Innovation Action ☐ SME Instrument

Work Programme research areas: indicate your interest

Call topic(s):

Do you have other partners for this topic (which partners/country)?

Profile of partner sought

Role: ☐ technology development ☐ research ☐ training
☐ dissemination ☐ demonstration ☐ other:

Country /region:

Expertise required:

I agree with the publication of my contact data: ☐ YES ☐ NO

 **HNN3.0**
HEALTH-NCP-NET

Health NCP Net
Partner Search
How to search partners and get noticed

www.healthncp.net

 HNN3.0 (The Cluster 1 Health consortium of NCPs for Horizon Europe) has received funding from the European Union's Horizon EUROPE research and innovation programme under Grant Agreement number 101057279

**TÜBİTAK Destek Programları ile ekosistem aktörlerimizi
cesaretlendiriyor, başarılarını teşvik ediyoruz.**



HORIZON EUROPE

- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Vaccines Europe
- MedTech Europe
- EuropaBio
- COCIR
- Nanomedicine European Technology Platform
- ECH Alliance



Ufuk Avrupa Web Sitesi-Sağlık Kümesi



- Çağrı dokümanları ve önemli dokümanlar
- Haberler
- Etkinlik duyuruları
- Başarı Hikayeleri




Informing and awareness raising
on Horizon Europe and other EU programmes



Assisting, advising and training
to improve the quality of Horizon Europe proposals



Signposting and cooperation
highlighting support avail. & supporting consortium development



Webinar on the annotated Horizon Europe template: "Information on Clinical Studies"

13. November 2023
10:00 – 11:30 (CET) www.healthncp.net

Değerli Araştırmacılar,

Ufuk Avrupa Sağlık Kümesi, Yenilikçi Sağlık Girişimi (iHi) ve Kansere Misyonu çağrılarında sunulan klinik çalışma içeren tüm proje önerilerinde "Klinik Çalışmalar Bilgi Formu" nun doldurulması ve ek bir doküman olarak sisteme yüklenmesi gerekmektedir.

Sağlık Ulusal İrtibat Noktaları Ağı (The Health NCP Network 3.0-HNN3.0) tarafından bu forma ilişkin açıklamalı bir doküman hazırlanmıştır. Bu dokümanda güçlü bir proje önerisi yapmak için yorum, tavsiye ve öneriler yer almaktadır, ancak dokümanın resmi bir niteliği bulunmamaktadır.

Avrupa Komisyonu ve HNN3.0 Ağı tarafından Klinik Çalışmalar Bilgi Formunun nasıl doldurulması gerektiğine yönelik önemli bilgilerin paylaşılacağı bir webinar düzenlenecektir. Etkinlik, **13 Kasım 2023 tarihinde saat 11:00-12:30** arasında gerçekleşecek olup, katılım için [link](#) üzerinden kayıt yaptırabilirsiniz.

<https://ufukavrupa.org.tr/tr/alanlar-kumeler/saglik>



Email:

Abonenin e-posta adresi.

Abone olmak istediğiniz haber bülten(ler)ini seçiniz.

- ☐ Akademik İşbirliği - Academic Cooperation Calls
- ☐ Araştırma Altyapıları - Research Infrastructures
- ☐ Avrupa Araştırma Konseyi - European Research Council (ERC)
- ☐ Bilgi ve İletişim Teknolojileri - Information and Communication Technologies
- ☐ Çevre ve Hammaddeler - Environment and Raw Materials
- ☐ Enerji - Energy
- ☐ Gıda, Tarım, Denizcilik ve Biyoteknoloji - Food, Agriculture, Marine and Bioeconomy
- ☐ Güvenli Topluluklar - Secure Societies
- ☐ KOBİ İnovasyon Destekleri - SME Innovation Grants
- ☐ Malzeme ve İmalat Teknolojileri - Materials and Manufacturing Technologies
- ☐ Mükemmeliyetin Yayılımı ve Katılımın Genişletilmesi - Spreading Excellence and Widening Participation
- ☒ Sağlık - Health
- ☐ Sanayi İşbirliği - Industrial Cooperation Calls
- ☐ Sosyal ve Beşeri Bilimler - Social Sciences and Humanities
- ☐ Toplum ile Toplum için Bilim - Science with and for Society
- ☐ Ufuk2020 Yasal/Finansal Konular
- ☐ Ulaşım - Transport
- ☐ Marie Skłodowska Curie Eylemleri
- ☐ Uzay - Space
- ☐ Yeni ve Gelişen Teknolojiler - Future and Emerging Technologies

Abone olmak veya abonelikten çıkmak istediğiniz haber bültenlerini seçin.

☐ Ben robot değilim 

☐ KVKK Aydınlatma Metnini Okudum, Onaylıyorum.

KVKK aydınlatma metnine ulaşmak için tıklayınız.

Abone Ol

Aboneliği İptal Et

 Avrupa'nın Kanseri Yenme Planı-EU4Health Projelerinin İlk Tanıtımı
Kimden: info@ufukavrupa.org.tr
Kimin: "Selcan Nazife TÜRKER, BAŞKANLIK-SBAG" <selcan.turker@tubitak.gov.tr>

Avrupa'nın Kanseri Yenme Planı-EU4Health Projelerinin İlk Tanıtımı



 Sağlık Kümesi 2024 Yılı Çağrılarına Yönelik Çevrimiçi Proje Pazarı Kayıtları Açıldı!
Kimden: info@ufukavrupa.org.tr
Kimin: "Selcan Nazife TÜRKER, BAŞKANLIK-SBAG" <selcan.turker@tubitak.gov.tr>

Sağlık Kümesi 2024 Yılı Çağrılarına Yönelik Çevrimiçi Proje Pazarı Kayıtları Açıldı!



<https://ufukavrupa.org.tr/tr/e-bulten>



T.C. SANAYİ VE
TEKNOLOJİ BAKANLIĞI



Teşekkürler